{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:28:16Z","timestamp":1787016496223,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1124\/jpet.119.264895","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:25:14Z","timestamp":1588962314000},"page":"273-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters"],"prefix":"10.1016","volume":"374","author":[{"given":"Charlotte P.","family":"Magee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"German","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen H.","family":"Siripathane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana G.","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen R.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette E.","family":"Fleckenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.264895_bib1","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00213-015-3944-8","article-title":"In vivo potency and efficacy of the novel cathinone \u03b1-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats","volume":"232","author":"Aarde","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264895_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuropharm.2013.04.003","article-title":"The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats","volume":"71","author":"Aarde","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264895_bib3","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00213-014-3819-4","article-title":"Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats","volume":"232","author":"Aarde","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264895_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/adb.12201","article-title":"Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects","volume":"21","author":"Anizan","year":"2016","journal-title":"Addict Biol"},{"key":"10.1124\/jpet.119.264895_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/jnc.13048","article-title":"3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: \u03b2-ketoamphetamine modulation of neurotoxicity by the dopamine transporter","volume":"133","author":"Anneken","year":"2015","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.119.264895_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/7854_2016_53","article-title":"Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs","volume":"32","author":"Baumann","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1124\/jpet.119.264895_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/npp.2012.204","article-title":"Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive \u2018bath salts\u2019 products","volume":"38","author":"Baumann","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1124\/jpet.119.264895_bib46","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/mol.106.027763","article-title":"D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism","volume":"71","author":"Bolan","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.119.264895_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.brainres.2009.11.069","article-title":"Methamphetamine self-administration and the effect of contingency on monoamine and metabolite tissue levels in the rat","volume":"1317","author":"Brennan","year":"2010","journal-title":"Brain Res"},{"key":"10.1124\/jpet.119.264895_bib9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0022-3565(24)38814-7","article-title":"Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants","volume":"296","author":"Brown","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib10","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/mds.23263","article-title":"Incidence of Parkinson\u2019s disease among hospital patients with methamphetamine-use disorders","volume":"25","author":"Callaghan","year":"2010","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.119.264895_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2011.06.013","article-title":"Increased risk of Parkinson\u2019s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs","volume":"120","author":"Callaghan","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.119.264895_bib12","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/bph.12061","article-title":"Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter","volume":"168","author":"Cameron","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.264895_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/mds.22915","article-title":"Parkinsonism in patients with a history of amphetamine exposure","volume":"25","author":"Christine","year":"2010","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.119.264895_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuropharm.2018.04.031","article-title":"Functional connectivity, behavioral and dopaminergic alterations 24 hours following acute exposure to synthetic bath salt drug methylenedioxypyrovalerone","volume":"137","author":"Colon-Perez","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264895_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugalcdep.2014.10.027","article-title":"Methamphetamine\/amphetamine abuse and risk of Parkinson\u2019s disease in Utah: a population-based assessment","volume":"146","author":"Curtin","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.119.264895_bib16","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1006\/bbrc.2002.6384","article-title":"Cocaine increases dopamine uptake and cell surface expression of dopamine transporters","volume":"290","author":"Daws","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1124\/jpet.119.264895_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1046\/j.1471-4159.1999.0720148.x","article-title":"Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum","volume":"72","author":"Dickinson","year":"1999","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.119.264895_bib17","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bcp.2013.04.004","article-title":"Substituted methcathinones differ in transporter and receptor interactions","volume":"85","author":"Eshleman","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.119.264895_bib18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1124\/jpet.108.146159","article-title":"Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation","volume":"328","author":"Farnsworth","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-2999(99)00588-9","article-title":"Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function","volume":"382","author":"Fleckenstein","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264895_bib20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0022-3565(24)36858-2","article-title":"Rapid and reversible effects of methamphetamine on dopamine transporters","volume":"282","author":"Fleckenstein","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/jpet.110.176610","article-title":"Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia","volume":"336","author":"Frankel","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.116.239376","article-title":"Individual differences in the relative reinforcing effects of 3,4-methylenedioxypyrovalerone under fixed and progressive ratio schedules of reinforcement in rats","volume":"361","author":"Gannon","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.drugalcdep.2017.06.031","article-title":"Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice","volume":"179","author":"Gannon","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.119.264895_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.117.246082","article-title":"Inhibition of cocaine and 3,4-methylenedioxypyrovalerone (MDPV) self-administration by lorcaserin is mediated by 5-HT2C receptors in rats","volume":"364","author":"Gannon","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.neuro.2006.03.015","article-title":"Amphetamine exposure is elevated in Parkinson\u2019s disease","volume":"27","author":"Garwood","year":"2006","journal-title":"Neurotoxicology"},{"key":"10.1124\/jpet.119.264895_bib26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1471-4159.2012.07875.x","article-title":"Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization","volume":"123","author":"German","year":"2012","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.119.264895_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuropharm.2018.05.008","article-title":"Self-administration of the synthetic cathinone MDPV enhances reward function via a nicotinic receptor dependent mechanism","volume":"137","author":"Geste","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264895_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.108.145631","article-title":"Mechanisms underlying methamphetamine-induced dopamine transporter complex formation","volume":"329","author":"Hadlock","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/acschemneuro.5b00277","article-title":"Enhanced dopamine release by dopamine transport inhibitors described by a restricted diffusion model and fast-scan cyclic voltammetry","volume":"7","author":"Hoffman","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.119.264895_bib30","series-title":"Monitoring the future national survey results on drug use 1975-2018: overview, key findings on adolescent drug use","author":"Johnston","year":"2019"},{"key":"10.1124\/jpet.119.264895_bib31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00213-018-5052-z","article-title":"Effects of MDPV on dopamine transporter regulation in male rats. Comparison with cocaine","volume":"236","author":"Lopez-Arnau","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264895_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1124\/jpet.111.188433","article-title":"Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure","volume":"340","author":"McFadden","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuropharm.2005.05.004","article-title":"Bupropion increases striatal vesicular monoamine transport","volume":"49","author":"Rau","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264895_bib34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"key":"10.1124\/jpet.119.264895_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-2999(02)01985-4","article-title":"Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine","volume":"449","author":"Riddle","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264895_bib36","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.amjmed.2012.02.019","article-title":"Psychoactive \u201cbath salts\u201d intoxication with methylenedioxypyrovalerone","volume":"125","author":"Ross","year":"2012","journal-title":"Am J Med"},{"key":"10.1124\/jpet.119.264895_bib37","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1523\/JNEUROSCI.22-19-08705.2002","article-title":"Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors","volume":"22","author":"Sandoval","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.119.264895_bib38","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00213-015-4057-0","article-title":"Reinforcing and neurochemical effects of the \u201cbath salts\u201d constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats","volume":"233","author":"Schindler","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264895_bib39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.264895_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/15563650.2011.590812","article-title":"Clinical experience with and analytical confirmation of \u201cbath salts\u201d and \u201clegal highs\u201d (synthetic cathinones) in the United States","volume":"49","author":"Spiller","year":"2011","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1124\/jpet.119.264895_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2004.09.049","article-title":"Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein","volume":"504","author":"Truong","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264895_bib42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0026-895X(25)08605-5","article-title":"Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping","volume":"47","author":"Vaughan","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.119.264895_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.108.139386","article-title":"Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors","volume":"327","author":"Volz","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264895_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1369-1600.2012.00474.x","article-title":"Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)","volume":"19","author":"Watterson","year":"2014","journal-title":"Addict Biol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652425816X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652425816X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.264895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:11:15Z","timestamp":1739945475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652425816X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S002235652425816X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.264895","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.264895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}